NCT06441812View on ClinicalTrials.gov

A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Eosinophilic Asthma Patients

Interventions

DRUG

SHR-1703 Injection

SHR-1703 Injection

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY